Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 11:16:1564003.
doi: 10.3389/fendo.2025.1564003. eCollection 2025.

Editorial: Lipid metabolism dysregulation in obesity-related diseases and neurodegeneration

Jialiu Zeng #  1   2 , Chih Hung Lo #  2   3
Affiliations
Editorial

Editorial: Lipid metabolism dysregulation in obesity-related diseases and neurodegeneration

Jialiu Zeng et al. Front Endocrinol (Lausanne). .
No abstract available

Keywords: biomarker discovery; body-brain interactions; metabolic dysfunction; neurodegenerative diseases; neuroinflammation; obesity; therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Peripheral metabolic dysfunction drives brain disorders through pathological body-brain interactions. Peripheral fat accumulation in organs such as the liver and pancreas leads to metabolic dysfunction, accompanied by the release of high-density lipoprotein (HDL) cholesterol particles and inflammatory cytokines. These changes not only affect other peripheral organs, such as the gut and cardiovascular system, but also propagate to the brain, contributing to neuroinflammation and neurodegeneration. (A) Differential contributions of peripheral fat deposition: Hepatic fat plays a more significant role than pancreatic fat in metabolic dysfunction. Hepatic fat accumulation is associated with increased fasting blood glucose, elevated insulin levels, and greater insulin resistance. (B) Metabolic dysfunction elevates the risk of brain disorders: An increased non high density lipoprotein cholesterol (non-HDL-c) to HDL-c ratio negatively impacts cerebral blood flow, exacerbates microvascular dysfunction, and increases stroke risk. (C) Biomarkers of metabolic dysfunction: Serum Aβ42 levels positively correlate with serum triglyceride levels and diastolic blood pressure, while negatively correlating with HDL-c levels. (D) Therapeutic strategies: Pharmacological interventions can be applied to target metabolic dysfunction and its associated impact on the brain through increasing lipid clearance, increasing metabolic activity, and reducing inflammation. Created in BioRender.
See this image and copyright information in PMC

Comment on

  • Editorial on the Research Topic Lipid metabolism dysregulation in obesity-related diseases and neurodegeneration

Similar articles

See all similar articles

Cited by

References

    1. Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. (2020) 42:101092. doi: 10.1016/j.molmet.2020.101092 - DOI - PMC - PubMed
    1. Sourianarayanane A, Brydges CR, McCullough AJ. Liver tissue lipids in metabolic dysfunction-associated steatotic liver disease with diabetes and obesity. Clin Res Hepatol Gastroenterol. (2024) 48:102402. doi: 10.1016/j.clinre.2024.102402 - DOI - PubMed
    1. Tong B, Ba Y, Li Z, Yang C, Su K, Qi H, et al. . Targeting dysregulated lipid metabolism for the treatment of Alzheimer’s disease and Parkinson’s disease: Current advancements and future prospects. Neurobiol Dis. (2024) 196:106505. doi: 10.1016/j.nbd.2024.106505 - DOI - PubMed
    1. Mikkelsen ACD, Kjærgaard K, Schapira AHV, Mookerjee RP, Thomsen KL. The liver-brain axis in metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. (2024). doi: 10.1016/S2468-1253(24)00320-0 - DOI - PubMed
    1. De Cól JP, de Lima EP, Pompeu FM, Cressoni Araújo A, de Alvares Goulart R, Bechara MD, et al. . Underlying mechanisms behind the brain–gut–liver axis and metabolic-associated fatty liver disease (MAFLD): an update. Int J Mol Sci. (2024) 25:3694. doi: 10.3390/ijms25073694 - DOI - PMC - PubMed

Publication types

LinkOut - more resources